IP Library › Granted Patent US 12,686,714

Granted Patent B2

US 12,686,714 · App. 18/475,358 · Granted Jul 21, 2026

Engineered dual binding antibodies and uses thereof

Inventors: Alik Demishtein (Rosh Haayin, IL); Shmuel Bernstein (Lod, IL); Tomer Shlamkovich (Modi'in-Maccabim-Re'ut, IL); Ayelet Chen (Jerusalem, IL); Yehezkel Sasson (Tzur Yigal, IL); Marek Strajbl (Jerusalem, IL); Itay Levin (Herzeliya, IL); Sharon Fischman (Modi'in, IL); Yanay Ofran (Tel Aviv, IL); Guy Nimrod (Tel Aviv, IL); Alexey Shnyder (Petah-Tiqva, IL); Hadar Gattegno (Rehovot, IL); Nikol Malchenko (Ramat Gan, IL); Olga Bluvshtein Yermolaev (Rishon-LeZion, IL); Noam Grossman (Mazkeret Batyia, IL); Liron Danielpur (Hadera, IL); Itzhak Meir (Rehovot, IL); Morya Ifrach (Qiryat Gat, IL); Reut Barak Fuchs (Rehovot, IL); Michael Zhenin (Jerusalem, IL); Yair Fastman (Jerusalem, IL)

Assignee: BIOLOJIC DESIGN LTD.

C07K16/244 C07K2317/31 C07K2317/33 C07K2317/52 C07K2317/622 C07K2317/732 C07K2317/76 C07K2317/92

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 12,686,714
App. No.: 18/475,358
Filed: Sep 27, 2023
Granted: Jul 21, 2026
Kind: B2
Examiner: DRISCOLL, LORA E BARNHART
Art Unit: 3991
USPC: 424/136.1

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Described herein are engineered dual binding antibodies that bind to IL-13 and TSLP and uses thereof. Uses include treating allergic and respiratory conditions. Described herein are also libraries comprising the engineered dual binding antibodies, and methods of producing the engineered dual binding antibodies and functional and biochemical characterization of the antibodies.

Claims (154)

1 . An isolated anti-IL-13, anti-TSLP dual binding antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein said VH comprises heavy chain complementarity determining regions (HCDRs) HCDR1, HCDR2, and HCDR3, and said VL comprises light chain complementarity determining regions (LCDRs) LCDR1, LCDR2, and LCDR3, wherein

(a) the HCDR1 comprises the amino acid sequence set forth in any one of SEQ ID NOs: 349, 355, 149 and 136;

(b) the HCDR2 comprises the amino acid sequence set forth in any one of SEQ ID NOs: 350, 352, 354, 356, and 150 or the sequence set forth as: I HX1 Y D G S N K (SEQ ID NO:142), wherein HX1 is any amino acid;

(c) the HCDR3 comprises the amino acid sequence set forth in any one of SEQ ID NOs: 351, 353, 357, 358, and 151 or the sequence set forth as: A R HX2 HX3 HX4 HX5 HX6 HX7 HX8 HX9 HX10 HX11 F D HX12 (SEQ ID NO:143), wherein HX2, HX3, HX4, HX5, HX6, HX7, HX8, HX9, HX10, HX11, and HX12 are any amino acid;

(d) the LCDR1 comprises the amino acid sequence of one of SEQ ID NOs: 364, 359, 362, 366, and 152 or the sequence set forth as LX1, LX2, G S K LX3 V (SEQ ID NO:144), wherein LX1, LX2, and LX3 are any amino acid;

(e) the LCDR2 comprises the amino acid sequence of DDV or DDS, or the sequence set forth as D D LX4, wherein LX4 is any amino acid; and

(f) the LCDR3 comprises the amino acid sequence set forth in any one of SEQ ID NOs: 384, 361, 363, 365, 368, 370-374, 376-383, 385-407, and 154 or the sequence set forth as Q V W D LX5 LX6 S D LX7 V V (SEQ ID NO:146), wherein LX5, LX6, and LX7 are any amino acid.

2 . The isolated dual binding antibody of claim 1 , wherein the amino acid sequences of the HCDRs and LCDRs of said antibody are selected from any one of the following sets:

(a) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 349, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 364, LCDR2 comprises the amino acid sequence DDV, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 384;

(b) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 349, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 354, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 364, LCDR2 comprises the amino acid sequence DDV, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 365;

(c) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 349, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 359, LCDR2 comprises the amino acid sequence DDV, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 361;

(d) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 349, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 356, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 364, LCDR2 comprises the amino acid sequence DDV, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 371;

(e) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 349, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 362, LCDR2 comprises the amino acid sequence DDV, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 384;

(f) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 349, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 352, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 353, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 362, LCDR2 comprises the amino acid sequence DDV, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 363;

(g) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 349, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 352, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 366, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 368;

(h) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 356, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 370;

(i) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 349, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 352, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 353, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 362, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 372;

(j) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 349, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 359, LCDR2 comprises the amino acid sequence DDV, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 373;

(k) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 349, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 364, LCDR2 comprises the amino acid sequence DDV, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 374;

(l) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 357, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 375, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 376;

(m) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 349, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 362, LCDR2 comprises the amino acid sequence DDV, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 377;

(n) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 356, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 378;

(o) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 356, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 379;

(p) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 349, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 359, LCDR2 comprises the amino acid sequence DDV, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 380;

(q) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 356, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 379;

(r) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 352, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 381;

(s) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 357, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 370;

(t) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 356, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 366, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 382;

(u) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 370;

(v) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 356, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 383;

(w) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 352, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 366, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 385;

(x) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 386;

(y) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 352, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 387;

(z) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 356, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 388;

(aa) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 356, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 389;

(bb) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 352, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 379;

(cc) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 352, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 390;

(dd) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 366, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 391;

(ee) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 375, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 392;

(ff) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 354, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 393;

(gg) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 356, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 394;

(hh) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 356, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 395;

(ii) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 396;

(jj) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 352, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 397;

(kk) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 398;

(ll) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 388;

(mm) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 394;

(nn) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 375, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 398;

(oo) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 352, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 357, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 375, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 399;

(pp) HCDR1 is set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 375, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 400;

(qq) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 357, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 375, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 398;

(rr) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 349, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 378;

(ss) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 375, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 401;

(tt) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 356, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 358, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 402;

(uu) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO:349, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 356, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 358, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 403;

(vv) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 356, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 358, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 375, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 376;

(ww) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 402;

(xx) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 349, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 353, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 359, LCDR2 comprises the amino acid sequence DDV, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 404;

(yy) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 357, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 375, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 405;

(zz) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 366, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 406;

(aaa) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 375, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 407; and

(bbb) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 354, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 379.

3 . The isolated dual binding antibody of claim 1 , wherein said VH and said VL comprise the amino acid sequences set forth in SEQ ID NOs: 337 and 338, respectively; SEQ ID NOs: 213 and 214, respectively; SEQ ID NOs: 209 and 210, respectively; SEQ ID NOs: 219 and 220, respectively; SEQ ID NOs: 249 and 250, respectively; SEQ ID NOs: 155 and 156, respectively; SEQ ID NOs: 157 and 158, respectively; SEQ ID NOs: 4 and 3, respectively; SEQ ID NOs: 6 and 5, respectively; SEQ ID NOs: 8 and 7, respectively; SEQ ID NOs: 10 and 9, respectively; SEQ ID NOs: 12 and 11, respectively; SEQ ID NOs: 14 and 13, respectively; SEQ ID NOs: 16 and 15, respectively; SEQ ID NOs: 18 and 17, respectively; SEQ ID NOs: 20 and 19, respectively; SEQ ID NOs: 22 and 21, respectively; SEQ ID NOs: 24 and 23, respectively; SEQ ID NOs: 26 and 25, respectively; SEQ ID NOs: 28 and 27, respectively; SEQ ID NOs: 30 and 29, respectively; SEQ ID NOs: 32 and 31, respectively; SEQ ID NOs: 34 and 33, respectively; SEQ ID NOs: 36 and 35, respectively; SEQ ID NOs: 38 and 37, respectively; SEQ ID NOs: 40 and 39, respectively; SEQ ID NOs: 42 and 41, respectively; SEQ ID NOs: 44 and 43, respectively; SEQ ID NOs: 46 and 45, respectively; SEQ ID NOs: 48 and 47, respectively; SEQ ID NOs: 50 and 49, respectively; SEQ ID NOs: 52 and 51, respectively; or SEQ ID NOs: 54 and 53, respectively.

4 . The isolated dual binding antibody of claim 1 , wherein said antibody comprises an IgG, an Fv, an scFv, an Fab, an F (ab′) 2 , a minibody, a diabody, or a triabody, wherein said IgG is IgG1, IgG2, IgG3, or IgG4.

5 . The isolated dual binding antibody of claim 4 , wherein said IgG comprises a heavy chain (HC) comprising a mutation that reduces binding to an Fc receptor, wherein said dual binding antibody comprising this mutation is unable to bind to antibody-dependent cellular cytotoxicity components.

6 . The isolated dual binding antibody of claim 5 , wherein said mutation is a L234A L235A P329G (LALAPG) mutation or a L234A L235A (LALA) mutation.

7 . The isolated dual binding antibody of claim 6 , wherein said VH and said VL comprise the amino acid sequences set forth in SEQ ID NOs: 337 and 338, respectively, and said antibody comprises said L234A L235A P329G (LALAPG) mutation or said L234A L235A (LALA) mutation.

8 . The isolated dual binding antibody of claim 7 , wherein said antibody comprises a heavy chain (HC) and a light chain (LC), and wherein the amino acid sequence of said HC and LC are set forth in SEQ ID NOs: 408 and 409, respectively, or SEQ ID NOs: 410 and 409, respectively.

9 . A composition comprising the isolated dual binding antibody of claim 1 and a pharmaceutically acceptable carrier.

10 . An isolated polynucleotide construct encoding the isolated dual binding antibody of claim 1 .

11 . An expression vector comprising the polynucleotide construct of claim 10 .

12 . A host cell comprising the expression vector of claim 11 .

13 . An isolated anti-IL-13, anti-TSLP dual binding antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein said VH comprises heavy chain complementarity determining regions (HCDRs) HCDR1, HCDR2, and HCDR3, said VL comprises light chain complementarity determining regions (LCDRs) LCDR1, LCDR2, and LCDR3, wherein the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs: 349, 350, and 351, respectively, and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NO: 364, DDV and SEQ ID NO: 384, respectively.

14 . An isolated anti-IL-13, anti-TSLP dual binding antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein said VH and said VL comprise the amino acid sequences set forth in SEQ ID NOs: 337 and 338, respectively.

15 . An isolated anti-IL-13, anti-TSLP dual binding antibody, comprising a heavy chain (HC) comprising a heavy chain variable region (VH) and a light chain (LC) comprising a light chain variable region (VL), wherein said HC comprises a L234A L235A P329G (LALAPG) mutation or a L234A L235A (LALA) mutation, and wherein the amino acid sequences of said VH and VL are set forth in SEQ ID NOs: 337 and 338, respectively.

16 . The isolated dual binding antibody of claim 15 , wherein the amino acid sequences of said HC and LC are set forth in SEQ ID NOs: 408 and 409, respectively, or SEQ ID NOs: 410 and 409, respectively.

17 . A method of treating a subject suffering from a disease or condition, said method comprises administering to said subject a composition comprising an isolated anti-IL-13, anti-TSLP dual binding antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein said VH comprises heavy chain complementarity determining regions (HCDRs) HCDR1, HCDR2, and HCDR3, said VL comprises light chain complementarity determining regions (LCDRs) LCDR1, LCDR2, and LCDR3, wherein

(a) the HCDR1 comprises the amino acid sequence set forth in any one of SEQ ID NOs: 349, 355, 149 and 136;

(c) the HCDR3 comprises the amino acid sequence set forth in any one of SEQ ID NOs: 351, 353, 357, 358, and 151 or the sequence set forth as: A R HX2 HX3 HX4 HX5 HX6 HX7 HX8 HX9 HX10 HX11 F D HX12 (SEQ ID NO: 143), wherein HX2, HX3, HX4, HX5, HX6, HX7, HX8, HX9, HX10, HX11, and HX12 are any amino acid;

(d) the LCDR1 comprises the amino acid sequence of one of SEQ ID NOs: 364, 359, 362, 366, 369, 375, and 152 or the sequence set forth as LX1, LX2, G S K LX3 V (SEQ ID NO:144), wherein LX1, LX2, and LX3 are any amino acid;

(e) the LCDR2 comprises the amino acid sequence of DDV or DDS, or the sequence set forth as D D LX4, wherein LX4 is any amino acid; and

18 . The method of claim 17 , wherein the amino acid sequences of the HCDRs and LCDRs of said antibody are selected from any one of the following sets:

LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369,

LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 370;

(v) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 356,

HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,

LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369,

LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 383;

(w) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 352,

HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,

LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 366,

LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 385;

(x) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 350,

HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351,

LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369, LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 386;

(y) HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 355, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 352,

HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 351, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 369,

LCDR2 comprises the amino acid sequence DDS, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 387;

19 . The method of claim 17 , wherein said disease or condition is an allergic or respiratory condition, an inflammatory or autoimmune condition, or tumors or cancers.

20 . The method of claim 17 , wherein said disease or condition is asthma, allergic asthma, nonallergic asthma, severe asthma, mild asthma, chronic obstructive pulmonary disease (COPD), a condition involving airway inflammation, cystic fibrosis, allergic lung disease, airway hyperresponsiveness, goblet cell metaplasia, mucus hypersecretion, airway remodeling, pulmonary fibrosis, atopic dermatitis, urticaria, eczema, allergic enterogastritis, allergic rhinitis, inflammatory bowel diseases, liver cirrhosis or fibrosis, or a combination thereof.

21 . A method of treating a subject suffering from a disease or condition, said method comprises administering to said subject a composition comprising an isolated anti-IL-13, anti-TSLP dual binding antibody comprising a heavy chain (HC) comprising a heavy chain variable region (VH) and a light chain (LC) comprising a light chain variable region (VL), wherein said HC comprises a L234A L235A P329G (LALAPG) mutation or a L234A L235A (LALA) mutation, and wherein the amino acid sequences of said VH and VL are set forth in SEQ ID NOs: 337 and 338, respectively.

22 . The method of claim 21 , wherein amino acid sequences of said HC and LC are set forth in SEQ ID NOs: 408 and 409, respectively, or SEQ ID NOs: 410 and 409, respectively.

Assignments (2)

SECURITY INTEREST Recorded Feb 5, 2025

From: BIOLOJIC DESIGN LTD.

To: WTI FUND X, INC.; WTI FUND XI, INC.

Reel/Frame 070123/0381 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 10, 2024

From: DEMISHTEIN, ALIK; BERNSTEIN, SHMUEL; SHLAMKOVICH, TOMER; CHEN, AYELET; SASSON, YEHEZKEL; STRAJBL, MAREK; LEVIN, ITAY; FISCHMAN, SHARON; OFRAN, YANAY; NIMROD, GUY; SHNYDER, ALEXEY; GATTEGNO, HADAR; MALCHENKO, NIKOL; BLUVSHTEIN YERMOLAEV, OLGA; GROSSMAN, NOAM; DANIELPUR, LIRON; MEIR, ITZHAK; IFRACH, MORYA; BARAK FUCHS, REUT; ZHENIN, MICHAEL; FASTMAN, YAIR

To: BIOLOJIC DESIGN LTD.

Reel/Frame 068864/0081 →

Continuity (6)

Continuation In Part PCTIL2022050572 · May 29, 2022

Continuation In Part PCTIL2022050087 · Jan 20, 2022

Provisional Application 63195021 · May 30, 2021

Provisional Application 63295905 · Jan 2, 2022

Related Publication 20240059769A1 · Feb 22, 2024

Related Publication 20240409625A9 · Dec 12, 2024

References Cited (219)

US 4237224A · Cohen et al. · 1980 [cited by applicant]

US 4751180A · Cousens et al. · 1988 [cited by applicant]

US 4816567A · Cabilly et al. · 1989 [cited by applicant]

US 4935233A · Bell et al. · 1990 [cited by applicant]

US 5151510A · Stec et al. · 1992 [cited by applicant]

US 5585089A · Queen et al. · 1996 [cited by applicant]

US 5693762A · Queen et al. · 1997 [cited by applicant]

US 5837458A · Minshull et al. · 1998 [cited by applicant]

US 7829090B2 · Monk et al. · 2010 [cited by applicant]

US 7935343B2 · Monk et al. · 2011 [cited by applicant]

US 7947273B2 · Monk et al. · 2011 [cited by applicant]

US 7982016B2 · Comeau et al. · 2011 [cited by applicant]

US 8008449B2 · Korman et al. · 2011 [cited by applicant]

US 8133979B2 · Brinkmann et al. · 2012 [cited by applicant]

US 8163284B2 · Comeau et al. · 2012 [cited by applicant]

US 8361747B2 · Brinkmann et al. · 2013 [cited by applicant]

US 8394378B2 · Kehoe et al. · 2013 [cited by applicant]

US 8399626B2 · Brinkmann et al. · 2013 [cited by applicant]

US 8637019B2 · Presta · 2014 [cited by applicant]

US 9284372B2 · Comeau et al. · 2016 [cited by applicant]

US 9856317B2 · Monk et al. · 2018 [cited by applicant]

US 9879072B2 · Richards et al. · 2018 [cited by applicant]

US 9889423B2 · Banyai et al. · 2018 [cited by applicant]

US 10138298B2 · Rondon et al. · 2018 [cited by applicant]

US 10259881B2 · Gray et al. · 2019 [cited by applicant]

US 10287348B2 · Comeau et al. · 2019 [cited by applicant]

US 10738113B2 · Rondon et al. · 2020 [cited by applicant]

US 10828365B2 · Parnes et al. · 2020 [cited by applicant]

US 10870705B2 · Marasco · 2020 [cited by applicant]

US 11459385B2 · Rondon et al. · 2022 [cited by applicant]

US 20090238823A1 · Comeau et al. · 2009 [cited by applicant]

US 20090304693A1 · Ghayur et al. · 2009 [cited by applicant]

US 20120020988A1 · Auer et al. · 2012 [cited by applicant]

US 20130045492A1 · Babb et al. · 2013 [cited by applicant]

US 20130259867A1 · Amler et al. · 2013 [cited by applicant]

US 20160264658A1 · Ahmed et al. · 2016 [cited by applicant]

US 20160272706A1 · Carmen et al. · 2016 [cited by applicant]

US 20170066823A1 · Edwards et al. · 2017 [cited by applicant]

US 20170082608A1 · Gorski et al. · 2017 [cited by applicant]

US 20170342144A1 · Wei et al. · 2017 [cited by applicant]

US 20170362321A1 · Campbell et al. · 2017 [cited by applicant]

US 20180068055A1 · Ofran et al. · 2018 [cited by applicant]

US 20180296669A1 · Parnes et al. · 2018 [cited by applicant]

US 20190106488A1 · Rondon et al. · 2019 [cited by applicant]

US 20200283508A1 · Ko et al. · 2020 [cited by applicant]

US 20210040189A1 · Richards et al. · 2021 [cited by applicant]

US 20210052726A1 · Parnes et al. · 2021 [cited by applicant]

US 20210188965A1 · Rommelaere · 2021 [cited by examiner]

US 20230340106A1 · Rondon et al. · 2023 [cited by applicant]

US 20240101675A1 · Demishtein · 2024 [cited by examiner]

EP 1942939B2 · 2018 [cited by applicant]

WO WO1990004036A1 · 1990 [cited by applicant]

WO WO1991010741A1 · 1991 [cited by applicant]

WO WO1992003918A1 · 1992 [cited by applicant]

WO WO1994002602A1 · 1994 [cited by applicant]

WO WO1996033735A1 · 1996 [cited by applicant]

WO WO2005007699 · 2005 [cited by applicant]

WO WO2008027236 · 2008 [cited by applicant]

WO WO2009035577 · 2009 [cited by applicant]

WO WO2010017468A1 · 2010 [cited by applicant]

WO WO2012163520A1 · 2012 [cited by applicant]

WO WO2014086496A1 · 2014 [cited by applicant]

WO WO2015095539 · 2015 [cited by applicant]

WO WO2016086185A1 · 2016 [cited by applicant]

WO WO2016142426A1 · 2016 [cited by applicant]

WO WO2017042701A1 · 2017 [cited by applicant]

WO WO2017220988A1 · 2017 [cited by applicant]

WO WO2018191497 · 2018 [cited by applicant]

WO WO2020006486A1 · 2020 [cited by applicant]

WO WO2020094834A1 · 2020 [cited by applicant]

WO WO2020223392A2 · 2020 [cited by applicant]

WO WO2020264318A1 · 2020 [cited by applicant]

WO WO2021001653A1 · 2021 [cited by applicant]

WO WO2021116182 · 2021 [cited by applicant]

WO WO2022157773A2 · 2022 [cited by applicant]

WO WO2023164288A2 · 2023 [cited by applicant]

Venkataramani S et al. “Design and characterization of Zweimab and Doppelmab, high affinity dual antagonistic anti-TSLP/IL13 bispecific antibodies.” Biochem Biophys Res Commc'ns 504: 19-24. (Year: 2018). [cited by examiner]

Beard et al. Applying Physics-Based Scoring to Calculate Free Energies of Binding for Single Amino Acid Mutations in Protein-Protein Complexes PLoS One. 2013;8(12). [cited by applicant]

Beiboer et al. “Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent” Journal of molecular… [cited by applicant]

Benatuil et al. “An improved yeast transformation method for the generation of very large human antibody libraries” Protein engineering, design & selection: PEDS. Apr. 2010;23(4):155-9. [cited by applicant]

Chao et al. “Isolating and engineering human antibodies using yeast surface display” Nature protocols. 2006;1(2):755-68. [cited by applicant]

Chaudhary et al. “A rapid method of cloning functional variable-region antibody genes in [cited by applicant]

Chothia et al. “Canonical structures for the hypervariable regions of immunoglobulins” Journal of molecular biology. Aug. 20, 1987;196(4):901-17. [cited by applicant]

Corren et al. “The effect of tezepelumab on exacerbations in patients with severe, uncontrolled asthma according to baseline serum IL-5 and IL-13 levels: results from the phase 2b Pathway study” In B101. New Biological … [cited by applicant]

Davis et al. “SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies” Protein engineer… [cited by applicant]

Duperret et al. “Synthetic DNA-encoded monoclonal antibody delivery of anti-CTLA-4 antibodies induces tumor shrinkage in vivo” Cancer research. Nov. 11, 2018;78(22):6363. [cited by applicant]

Fellouse et al. “High-throughput generation of synthetic antibodies from highly functional minimalist phage-displayed libraries” Journal of molecular biology. Nov. 2, 2007;373(4):924-40. [cited by applicant]

Fischer et al. “Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG” Nature Communications. 2015, 6.6113. [cited by applicant]

Francis et al. “A novel xenograft model to study the role of TSLP-induced CRLF2 signals in normal and malignant human B lymphopoiesis” Haematologica. Apr. 2016;101(4):417. [cited by applicant]

Graham et al. “Characteristics of a human cell line transformed by DNA from human adenovirus type 5” The Journal of general virology. Jul. 1977;36(1):59-74. [cited by applicant]

Guss et al. “Structure of the IgG-binding regions of streptococcal protein G” The EMBO journal. Jul. 1986;5(7):1567-75. [cited by applicant]

Hanania et al. “Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies” Thorax. Aug. 2015;70(8):748. [cited by applicant]

Hudson et al. “Engineered antibodies” Nature medicine. Jan. 2003;9(1):129-34. [cited by applicant]

International Search Report for PCT Application No. PCT/IL2022/050572 dated Nov. 14, 2022. [cited by applicant]

Kienast et al. “Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy” Clinical cancer r… [cited by applicant]

Klimka et al. “Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning” British journal of cancer. Jul. 2000;83(2):252-60. [cited by applicant]

Labrijn et al. “Bispecific antibodies: a mechanistic review of the pipeline” Nature reviews. Drug discovery. Aug. 2019;18(8):585-608. [cited by applicant]

Laplanche et al. “Phosphorothioate-modified oligodeoxyribonucleotides. III. NMR and UV spectroscopic studies of the Rp-Rp, Sp-Sp, and Rp-Sp duplexes, [d (GGSAATTCC)] 2, derived from diastereomeric O-ethyl phosphorothioa… [cited by applicant]

Lefranc et al. “IMGT®, the international ImMunoGeneTics information system® 25 years on” Nucleic Acids Research. Jan. 1, 2015,43(Database issue):D413. [cited by applicant]

Lefranc et al. “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains” Developmental and comparative immunology. Jan. 2003;27(1):55-77. [cited by applicant]

Murphy et al. “Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria toxin-related alpha-melanocyte-stimulating hormone fusion protein” Proceedings of the National Academy of Sciences of … [cited by applicant]

Nakajima et al. “Anti-TSLP antibodies: Targeting a master regulator of type 2 immune responses” Allergology international: official journal of the Japanese Society of Allergology. Apr. 2020;69(2):197-203. [cited by applicant]

Niedziela-Majka et al. “High-throughput screening of formulations to optimize the thermal stability of a therapeutic monoclonal antibody” Journal of biomolecular screening. Apr. 2015;20(4):552-9. [cited by applicant]

Nilson et al. “Protein L from [cited by applicant]

Nimrod et al. “Computational Design of Epitope-Specific Functional Antibodies” Cell reports. Nov. 20, 2018;25(8):2121-31. [cited by applicant]

Nygaard et al. “TSLP, IL-31, IL-33 and sST2 are new biomarkers in endophenotypic profiling of adult and childhood atopic dermatitis” Journal of the European Academy of Dermatology and Venereology: JEADV. Nov. 2016;30(11… [cited by applicant]

Ofran et al. “Automated identification of complementarity determining regions (CDRs) reveals peculiar characteristics of CDRs and B cell epitopes” Journal of immunology (Baltimore, Md.: 1950). Nov. 1, 2008,181(9):6230-5. [cited by applicant]

Rader et al. “A phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries” Proceedings of the National Academy of Sciences of the United States of America. Jul. 7, 1998;95(15):8910. [cited by applicant]

Ridgway et al. “‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization” Protein engineering. Jul. 1996;9(7):617-21. [cited by applicant]

Salam et al. “Structure-based approach to the prediction of disulfide bonds in proteins” Protein engineering, design & selection: PEDS. Oct. 2014;27(10):365-74. [cited by applicant]

Simpson et al. “Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial” Journal of the American Academy of D… [cited by applicant]

Soumelis et al. “Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP” Nature immunology. Jul. 2002;3(7):673-80. [cited by applicant]

Stein et al. “Physicochemical properties of phosphorothioate oligodeoxynucleotides” Nucleic acids research. Apr. 25, 1988;16(8):3209-21. [cited by applicant]

Tabasinezhad et al. “Trends in therapeutic antibody affinity maturation: From in-vitro towards next-generation sequencing approaches” Immunology letters. Aug. 2019;212:106-13. [cited by applicant]

Thom et al. “Probing a protein-protein interaction by in vitro evolution” Proceedings of the National Academy of Sciences of the United States of America. May 5, 2006;103(20):7619. [cited by applicant]

Urlaub et al. “Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity” Proceedings of the National Academy of Sciences of the United States of America. Jul. 1980;77(7):4216. [cited by applicant]

Vannella et al. “Combinatorial targeting of TSLP, IL-25, and IL-33 in type 2 cytokine-driven inflammation and fibrosis” Science translational medicine. May 4, 2016;8(337):337ra65. [cited by applicant]

Venkataramani et al. “Design and characterization of Zweimab and Doppelmab, high affinity dual antagonistic anti-TSLP/IL 13 bispecific antibodies” Biochemical and biophysical research communications. Sep. 26, 2018;504(1… [cited by applicant]

Wollenberg et al. “Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)” The British Journal… [cited by applicant]

Wollenberg et al. “Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb” The Journal of allergy and clinical immunology. Jan. 2019;143(1):135-41. [cited by applicant]

Wu et al. “An Analysis of the Sequences of the Variable Regions of Bence Jones Proteins and Myeloma Light Chains and Their Implications for Antibody Complementarity” The Journal of Experimental Medicine. Aug. 8, 1970;13… [cited by applicant]

Zhu et al. “Antibody structure determination using a combination of homology modeling, energy-based refinement, and loop prediction” Proteins. Aug. 2014;82(8):1646-55. [cited by applicant]

Eger, et al., “The emergence of new biologics for severe asthma”, Current Opinion in Pharmacology, vol. 46, Jun. 1, 2019, pp. 108-115. [cited by applicant]

Matera, et al., “TSLP Inhibitors for Asthma: Current Status and Future Prospects”, Drugs, vol. 8, No. 5, Apr. 1, 2020, pp. 449-458. [cited by applicant]

Miyata, et al., “Thymic stromal lymphopoietin is a critical mediator of IL-13-driven allergic inflammation”, European Journal of Immunology, vol. 39, No. 11, Aug. 5, 2009, pp. 3078-3083. [cited by applicant]

Bostrom, et al., “High Affinity Antigen Recognition of the Dual Specific Variants of Herceptin is Entropy-Driven in Spite of Structural Plasticity”, PLoS One, Apr. 2011, vol. 6, Issue 4, pp. 1-12. [cited by applicant]

Bostrom, et al., “Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site”, Science, Mar. 20, 2009, vol. 323(5921): 1610-1614. [cited by applicant]

Eigenbrot, et al., “Two-in-One antibodies with dual action Fabs”, Current Opinion in Chemical Biology 2013, vol. 17(3): 400-405. [cited by applicant]

Lee, et al., “A Two-in-One antibody engineered from a humanized interleukin 4 antibody through mutation in heavy chain complementarity determining regions”, mAbs, Mar. 11, 2014, vol. 6, Issue 3, pp. 622-627. [cited by applicant]

Parren, et al., “Two-in-One Designer Antibodies”, Science, Mar. 20, 2009, vol. 323 (5921): 1567-1568. [cited by applicant]

Schaefer, et al., “A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies”, Cancer Cell Oct. 18, 2011, 20(4): 472-486. [cited by applicant]

Venkataramani, et al., “Design and characterization of Zweimab and Doppelmab, high affinity dual antagonistic anti-TSLP/IL13 bispecific antibodies” Biochemical and Biophysical Research Communications, 2018,504(1): 19-24. [cited by applicant]

Allakhverdi et al. “Thymic stromal lymphopoietin as a mediator of crosstalk between bronchial smooth muscles and mast cells” Journal of Allergy and Clinical Immunology. Apr. 1, 2009;123(4):958-60. [cited by applicant]

Allakhverdi et al. “Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells” The Journal of experimental medicine. Feb. 19, 2… [cited by applicant]

American Thoracic Society; European Respiratory Society. “ATS / ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 20… [cited by applicant]

Antonicelli et al. “Asthma severity and medical resource utilisation” The European Respiratory Journal. May 1, 2004;23(5):723-9. [cited by applicant]

Barnes et al. “Risk of severe life threatening asthma” Thorax. Nov. 1996;51(11):1073. [cited by applicant]

Bateman et al. “Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study” American journal of respiratory and critical care medicine. Oct. 15, 2004;170(8):836-44. [cited by applicant]

Bates et al. “Animal models of asthma” American Journal of Physiology—Lung Cellular and Molecular Physiology. Sep. 2009;297(3):L401-10. [cited by applicant]

Beckmann et al. “DutaFabs are engineered therapeutic Fab fragments that can bind two targets simultaneously” Nature communications. Jan. 29, 2021;12(1):708. [cited by applicant]

Bel EH. “Moving upstream—Anti-TSLP in persistent uncontrolled asthma” New England Journal of Medicine. Sep. 7, 2017;377(10):989-91. [cited by applicant]

Bel et al. “Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma” New England journal of medicine. Sep. 25, 2014;371(13): 1189-97. [cited by applicant]

Bleck et al. “Diesel exhaust particle-exposed human bronchial epithelial cells induce dendritic cell maturation and polarization via thymic stromal lymphopoietin” Journal of clinical immunology. Mar. 2008;28:147-56. [cited by applicant]

Bleecker et al. “Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-contro… [cited by applicant]

Brightling et al. “Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial” The Lancet Respiratory Medicine. Sep. 1, 2015;3(9):692-… [cited by applicant]

Brightling et al. “Targeting TNF-α: a novel therapeutic approach for asthma” Journal of Allergy and Clinical Immunology. Jan. 1, 2008;121(1):5-10. [cited by applicant]

Calven et al. “Viral stimuli trigger exaggerated thymic stromal lymphopoietin expression by chronic obstructive pulmonary disease epithelium: role of endosomal TLR3 and cytosolic RIG-I-like helicases” Journal of innate … [cited by applicant]

Castro et al. “Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials” The Lancet Respir… [cited by applicant]

Chen et al. “Neutralization of TSLP inhibits airway remodeling in a murine model of allergic asthma induced by chronic exposure to house dust mite” Plos One (2013): e51268. [cited by applicant]

Chung et al. “International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma” European respiratory journal. Feb. 1, 2014;43(2):343-73. [cited by applicant]

Corren et al. “Lebrikizumab treatment in adults with asthma” New England Journal of Medicine. Sep. 22, 2011;365(12):1088-98. [cited by applicant]

Corren et al. “Tezepelumab demonstrates clinically meaningful improvements in asthma control (ACQ-6) in patients with uncontrolled asthma: results from a phase 2b clinical trial” Journal of Allergy and Clinical Immunolo… [cited by applicant]

Corren et al. “Tezepelumab in adults with uncontrolled asthma” New England Journal of Medicine. Sep. 7, 2017;377(10):936-46. [cited by applicant]

Cukic et al. “Asthma and chronic obstructive pulmonary disease (COPD)—differences and similarities” Mater Sociomed. 2012;24(2):100-5. [cited by applicant]

Diamant et al. “Inhaled allergen bronchoprovocation tests” Journal of allergy and clinical immunology. Nov. 1, 2013;132(5):1045-55. [cited by applicant]

Dweik et al. “American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide le… [cited by applicant]

“Early Data Demonstrate Anti-TSLP Therapy Reduces Early and Late Asthmatic Responses and Several Key Inflammatory Markers” 2014. https://www.amgen.com/newsroom/press-releases/2014/05/the-new-england-journal-of-medicine-… [cited by applicant]

Fajt et al. “Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care” Journal of Allergy and Clinical Immunology. Feb. 1, 2015;135(2):299-310. [cited by applicant]

Fitzgerald et al. “Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-contro… [cited by applicant]

Froidure et al. “Asthma phenotypes and IgE responses” European Respiratory Journal. Dec. 31, 2015;47(1):304-19. [cited by applicant]

Gauvreau et al. “Effects of an anti-TSLP antibody on allergen-induced asthmatic responses” New England Journal of Medicine. May 29, 2014;370(22):2102-10. [cited by applicant]

Gavala et al. “Virus/allergen interactions in asthma” Current allergy and asthma reports. Jun. 2013;13:298-307. [cited by applicant]

Gilliet et al. “Human dendritic cells activated by TSLP and CD40L induce proallergic cytotoxic T cells” The Journal of experimental medicine. Apr. 21, 2003;197(8):1059-63. [cited by applicant]

“Global strategy for asthma management and prevention” GINA Report. Aug. 2014. https://ginasthma.org/reports/. [cited by applicant]

Hanania et al. “Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study” American journal of respiratory and critical care medicine. Apr. 15, 2013;187(8):804-11. [cited by applicant]

Jakobovits et al. “Analysis of homozygous mutant chimeric mice: deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production” Proceedings of the National Academy of Science… [cited by applicant]

Jakobovits et al. “Germ-line transmission and expression of a human-derived yeast artificial chromosome” Nature. Mar. 18, 1993;362(6417):255-8. [cited by applicant]

Jia et al. “Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients” Journal of Allergy and Clinical Immunology. Sep. 1, 2012;130(3):647-54. [cited by applicant]

Johansson et al. “Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, Oct. 2003” Journal of allergy and clinical immunology. May 1, 2004;113(5)… [cited by applicant]

Jones et al. “Replacing the complementarity-determining regions in a human antibody with those from a mouse” Nature. May 29, 1986;321(6069):522-5. [cited by applicant]

Juniper et al. “Determining a minimal important change in a disease-specific quality of life questionnaire” Journal of clinical epidemiology. Jan. 1, 1994;47(1):81-7. [cited by applicant]

Juniper et al. “Development and validation of a questionnaire to measure asthma control”. European respiratory journal. Oct. 1, 1999;14(4):902-7. [cited by applicant]

Juniper et al. “Identifying ‘well-controlled’ and ‘not well-controlled’ asthma using the Asthma Control Questionnaire” Respiratory medicine. Apr. 1, 2006;100(4):616-21. [cited by applicant]

Juniper et al. “Measurement properties and interpretation of three shortened versions of the asthma control questionnaire” Respiratory medicine. May 1, 2005;99(5):553-8. [cited by applicant]

Juniper et al. “Validation of a standardized version of the Asthma Quality of Life Questionnaire” Chest. May 1, 1999;115(5):1265-70. [cited by applicant]

Keene et al. “Analysis of exacerbation rates in asthma and chronic obstructive pulmonary disease: example from the TRISTAN study” Pharmaceutical Statistics: The Journal of Applied Statistics in the Pharmaceutical Indust… [cited by applicant]

Kemp et al. World Allergy Organization ad hoc Committee on Epinephrine in Anaphylaxis. “Epinephrine: the drug of choice for anaphylaxis—a statement of the World Allergy Organization” World Allergy Organization Journal. … [cited by applicant]

Kim et al. “TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation” Science translational medicine. Jan. 1, 2013;5(170):170ra16. [cited by applicant]

Lane et al. “An international observational prospective study to determine the Cost of Asthma exacerbations (COAX)” Respiratory Medicine. 2006;100:434-50. [cited by applicant]

Lee et al. “Thymic stromal lymphopoietin is induced by respiratory syncytial virus-infected airway epithelial cells and promotes a type 2 response to infection” The Journal of allergy and clinical immunology. Nov. 2012;… [cited by applicant]

Legrand et al. “Biologic Therapies Targeting Eosinophils: Current Status and Future Prospects” The journal of allergy and clinical immunology. In practice. Mar. 2015;3(2):167. [cited by applicant]

Li et al. “Periostin: its role in asthma and its potential as a diagnostic or therapeutic target” Respiratory Research. May 17, 2015;16:57. [cited by applicant]

May et al. Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma. British Journal of Pharmacology. May 2012;166(1):177. [cited by applicant]

Medimmune LL. “A phase 2 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of MEDI 9929 in adult subjects with inadequately controlled, severe asthma” 2013; Internet access at: o htt… [cited by applicant]

Miller et al. “General considerations for lung function testing” European Respiratory Journal. 2005;26(1):153-61. [cited by applicant]

Mishra et al. “From bedside to bench to clinic trials: identifying new treatments for severe asthma” Disease Models & Mechanisms. Jul. 2013;6(4):877. [cited by applicant]

Moore et al. “Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program” American Journal of Respiratory and Critical Care Medicine. Feb. 2, 2010;181(4):315. [cited by applicant]

Morrison et al. “Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains” Proceedings of the National Academy of Sciences. Nov. 1984;81(21):6851-5. [cited by applicant]

Nagata et al. “Differential role of thymic stromal lymphopoietin in the induction of airway hyperreactivity and Th2 immune response in antigen-induced asthma with respect to natural killer T cell function” International… [cited by applicant]

Nakamura et al. “Cigarette smoke extract induces thymic stromal lymphopoietin expression, leading to TH2-type immune responses and airway inflammation” Journal of Allergy and Clinical Immunology. Dec. 1, 2008;122(6):120… [cited by applicant]

Ortega et al. “Mepolizumab treatment in patients with severe eosinophilic asthma” New England journal of medicine. Sep. 25, 2014;371(13): 1198-207. [cited by applicant]

Park et al. “Cloning of the Murine Thymic Stromal Lymphopoietin (TSLP) Receptor: Formation of a Functional Heteromeric Complex Requires Interleukin 7 Receptor” The Journal of Experimental Medicine. Sep. 4, 2000;192(5):6… [cited by applicant]

Partridge MR. “Examining the unmet need in adults with severe asthma” European Respiratory Review. Sep. 1, 2007;16(104):67-72. [cited by applicant]

Paul et al. “How are TH2-type immune responses initiated and amplified?” Nature reviews. Immunology. Apr. 2010;10(4):225-35. [cited by applicant]

Pavord et al. “Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial” The Lancet. Aug. 18, 2012;380(9842):651-9. [cited by applicant]

Pavord et al. “The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting 2-agonists in the United Kingdom: a cross-sectional analysis” NPJ primary care respiratory med… [cited by applicant]

Rabe et al. “Worldwide severity and control of asthma in children and adults : the global asthma insights and reality surveys” Journal of Allergy and Clinical Immunology. Jul. 1, 2004;114(1):40-7. [cited by applicant]

Reche et al. “Human thymic stromal lymphopoietin preferentially stimulates myeloid cells” J Immunol 167: 336-343. [cited by applicant]

Riechmann et al. “Reshaping human antibodies for therapy” Nature. Mar. 24, 1988;332(6162):323-7. [cited by applicant]

Sampson et al. “Second symposium on the definition and management of anaphylaxis: Summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium” J Allergy Clin… [cited by applicant]

Sera-Batlles et al. “Costs of asthma according to the degree of severity” Eur Respir J. 1998;12:1322-6. [cited by applicant]

Shikotra et al. “Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma” Journal of allergy and clinical immunology. Jan. 1, 2012;129(1):104-11. [cited by applicant]

Sorkness et al. “Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation” J Appl Physiol. 2008;104:394-403. [cited by applicant]

Swedin et al. “Patient stratification and the unmet need in asthma” Pharmacology & therapeutics. Jan. 1, 2017;169:13-34. [cited by applicant]

Tabrizi et al. “Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease” The AAPS Journal. Mar. 2010;12(1):33. [cited by applicant]

Tanaka et al. “Human TSLP and TLR3 ligands promote differentiation of Th17 cells with a central memory phenotype under Th2-polarizing conditions” Clinical and Experimental Allergy. Jan. 2009;39(1):89. [cited by applicant]

To et al. “Global asthma prevalence in adults: findings from the cross-sectional world health survey” BMC public health. Dec. 2012;12:1-8. [cited by applicant]

Tough et al. “Features that distinguish those who die from asthma from community controls with asthma” Journal of Asthma. Jan. 1, 1998;35(8):657-65. [cited by applicant]

Trotta et al. “A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism” Nature medicine. Jul. 2018;24(7):1005-14. [cited by applicant]

Turner et al. “Risk factors for near-fatal asthma. A case-control study in hospitalized patients with asthma” American journal of respiratory and critical care medicine. Jun. 1998;157(6 Pt 1):1804-9. [cited by applicant]

Valladares et al. “Designing two-in-one antibodies” Immunotherapy. Sep. 1, 2009;1(5):749-51. [cited by applicant]

Verhoeyen et al. “Reshaping human antibodies: grafting an antilysozyme activity” Science. Mar. 25, 1988;239(4847):1534-6. [cited by applicant]

Wenzel et al. “Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-cont… [cited by applicant]

Wenzel SE. “Emergence of Biomolecular Pathways to Define Novel Asthma Phenotypes. Type-2 Immunity and Beyond” American Journal of Respiratory Cell and Molecular Biology. Jul. 2016;55(1):1. [cited by applicant]

Woodruff et al. “T-helper Type 2-driven Inflammation Defines Major Subphenotypes of Asthma” American Journal of Respiratory and Critical Care Medicine. Sep. 9, 2009;180(5):388. [cited by applicant]

Ying et al. “Expression and Cellular Provenance of Thymic Stromal Lymphopoietin and Chemokines in Patients with Severe Asthma and Chronic Obstructive Pulmonary Disease” Immunology. 2008;181:2790-8. [cited by applicant]

Ying et al. “Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity” The Journal of Immunology. Jun. 15, 2005;174(12):8… [cited by applicant]

Ziegler et al. “The biology of thymic stromal lymphopoietin (TSLP)” Adv Pharmacol. 2013;66:129-55. [cited by applicant]

Ragnoli et al., “Dupilumab and tezepelumab in severe refractory asthma: new opportunities”: Therapeutic Advances in Chronic Disease, 2022, vol. 13, pp. 1-19 (published online May 25, 2022). [cited by applicant]